{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:49:58Z","timestamp":1740163798543,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81900720","81700699","81700720","82070854"],"award-info":[{"award-number":["81900720","81700699","81700720","82070854"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>X-linked nephrogenic diabetes insipidus (X-linked NDI) is a rare inherited disease mainly caused by lost-of-function mutations in human <jats:italic>AVPR2<\/jats:italic> gene encoding arginine vasopressin receptor 2 (V2R). Our focus of the current study is on exploration of the functional and biochemical properties of Ile324Met (I324M) mutation identified in a pedigree showing as typical recessive X-linked NDI. We demonstrated that I324M mutation interfered with the conformation of complex glycosylation of V2R. Moreover, almost all of the I324M-V2R failed to express on the cell surface due to being captured by the endoplasmic reticulum control system. We further examined the signaling activity of DDAVP-medicated cAMP and ERK1\/2 pathways and the results revealed that the mutant receptor lost the ability in response to DDAVP stimulation contributed to the failure of accumulation of cAMP and phosphorylated ERK1\/2. Based on the characteristics of molecular defects of I324M mutant, we selected two reagents (SR49059 and alvespimycin) to determine whether the functions of I324M-V2R can be restored and we found that both compounds can significantly \u201crescue\u201d I324M mutation. Our findings may provide further insights for understanding the pathogenic mechanism of <jats:italic>AVPR2<\/jats:italic> gene mutations and may offer some implications on development of promising treatments for patients with X-linked NDI.<\/jats:p>","DOI":"10.1038\/s41598-021-90736-z","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T10:04:00Z","timestamp":1622023440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus"],"prefix":"10.1038","volume":"11","author":[{"given":"Lixia","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqiu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"90736_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/bs.vh.2019.08.012","volume":"113","author":"N Makita","year":"2020","unstructured":"Makita, N., Manaka, K., Sato, J. & Iiri, T. V2 vasopressin receptor mutations. Vitam. Horm. 113, 79\u201399 (2020).","journal-title":"Vitam. Horm."},{"key":"90736_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41572-019-0103-2","volume":"5","author":"M Christ-Crain","year":"2019","unstructured":"Christ-Crain, M. et al. Diabetes insipidus. Nat. Rev. Dis. Primers. 5, 54 (2019).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"90736_CR3","first-page":"886","volume":"8","author":"M Birnbaumer","year":"1994","unstructured":"Birnbaumer, M., Gilbert, S. & Rosenthal, W. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs\/adenylyl cyclase system. Mol. Endocrinol. 8, 886\u2013894 (1994).","journal-title":"Mol. Endocrinol."},{"key":"90736_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1172\/JCI8688","volume":"105","author":"JP Morello","year":"2000","unstructured":"Morello, J. P. et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest. 105, 887\u2013895 (2000).","journal-title":"J. Clin. Invest."},{"key":"90736_CR5","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3390\/cells9102172","volume":"9","author":"C Gao","year":"2020","unstructured":"Gao, C., Higgins, P. J. & Zhang, W. AQP2: mutations associated with congenital nephrogenic diabetes insipidus and regulation by post-translational modifications and protein\u2013protein interactions. Cells 9, 2172 (2020).","journal-title":"Cells"},{"key":"90736_CR6","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/ijms18112385","volume":"18","author":"S Milano","year":"2017","unstructured":"Milano, S., Carmosino, M., Gerbino, A., Svelto, M. & Procino, G. Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. An update. Int. J. Mol. Sci. 18, 2385 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"90736_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ecl.2017.01.002","volume":"46","author":"MH Schernthaner-Reiter","year":"2017","unstructured":"Schernthaner-Reiter, M. H., Stratakis, C. A. & Luger, A. Genetics of diabetes insipidus. Endocrinol. Metab. Clin. N. Am. 46, 305\u2013334 (2017).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"90736_CR8","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1073\/pnas.1936664100","volume":"100","author":"M Azzi","year":"2003","unstructured":"Azzi, M. et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. USA. 100, 11406\u201311411 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"90736_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cellsig.2006.05.020","volume":"19","author":"PG Charest","year":"2007","unstructured":"Charest, P. G., Oligny-Longpre, G., Bonin, H., Azzi, M. & Bouvier, M. The V2 vasopressin receptor stimulates ERK1\/2 activity independently of heterotrimeric G protein signalling. Cell Signal 19, 32\u201341 (2007).","journal-title":"Cell Signal"},{"key":"90736_CR10","doi-asserted-by":"publisher","first-page":"8397","DOI":"10.1073\/pnas.1509565112","volume":"112","author":"M Gao","year":"2015","unstructured":"Gao, M. et al. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proc. Natl. Acad. Sci. USA. 112, 8397\u20138402 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"90736_CR11","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/EJE-20-0114","volume":"183","author":"DG Bichet","year":"2020","unstructured":"Bichet, D. G. GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus. Eur. J. Endocrinol. 183, R29\u2013R40 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"90736_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ecl.2020.05.012","volume":"49","author":"J Refardt","year":"2020","unstructured":"Refardt, J., Winzeler, B. & Christ-Crain, M. Diabetes insipidus: an update. Endocrinol. Metab. Clin. N. Am. 49, 517\u2013531 (2020).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"90736_CR13","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.metabol.2012.01.005","volume":"61","author":"V Neocleous","year":"2012","unstructured":"Neocleous, V. et al. Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature. Metabolism 61, 922\u2013930 (2012).","journal-title":"Metabolism"},{"key":"90736_CR14","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1210\/jc.2002-020286","volume":"87","author":"A Schulz","year":"2002","unstructured":"Schulz, A. et al. Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus. J. Clin. Endocrinol. Metab. 87, 5247\u20135257 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"90736_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1124\/mol.109.061804","volume":"77","author":"MD Rochdi","year":"2010","unstructured":"Rochdi, M. D. et al. Functional characterization of vasopressin type 2 receptor substitutions (R137H\/C\/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol. Pharmacol. 77, 836\u2013845 (2010).","journal-title":"Mol. Pharmacol."},{"key":"90736_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/ki.2015.181","volume":"88","author":"LS Erdelyi","year":"2015","unstructured":"Erdelyi, L. S. et al. Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis. Kidney Int. 88, 1070\u20131078 (2015).","journal-title":"Kidney Int."},{"key":"90736_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10157-018-1544-8","volume":"22","author":"F Ando","year":"2018","unstructured":"Ando, F. & Uchida, S. Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus. Clin. Exp. Nephrol. 22, 501\u2013507 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"90736_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0008-6363(01)00337-6","volume":"51","author":"M Birnbaumer","year":"2001","unstructured":"Birnbaumer, M. The V2 vasopressin receptor mutations and fluid homeostasis. Cardiovasc. Res. 51, 409\u2013415 (2001).","journal-title":"Cardiovasc. Res."},{"key":"90736_CR19","doi-asserted-by":"publisher","first-page":"F257","DOI":"10.1152\/ajprenal.00491.2005","volume":"291","author":"JH Robben","year":"2006","unstructured":"Robben, J. H., Knoers, N. V. & Deen, P. M. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am. J. Physiol. Renal. Physiol. 291, F257\u2013F270 (2006).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"90736_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1681\/ASN.2008121289","volume":"20","author":"F Jean-Alphonse","year":"2009","unstructured":"Jean-Alphonse, F. et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 20, 2190\u20132203 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"90736_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-017-3390-x","volume":"80","author":"Q Yang","year":"2017","unstructured":"Yang, Q., Puhm, F., Freissmuth, M. & Nanoff, C. Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition. Cancer Chemother. Pharmacol. 80, 673\u2013684 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"90736_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1177\/0300060516655642","volume":"44","author":"WH Guo","year":"2016","unstructured":"Guo, W. H. et al. A novel AVPR2 gene mutation of X-linked congenital nephrogenic diabetes insipidus in an Asian pedigree. J. Int. Med. Res. 44, 1131\u20131137 (2016).","journal-title":"J. Int. Med. Res."},{"key":"90736_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/glycob\/9.7.731","volume":"9","author":"H Sadeghi","year":"1999","unstructured":"Sadeghi, H. & Birnbaumer, M. O-Glycosylation of the V2 vasopressin receptor. Glycobiology 9, 731\u2013737 (1999).","journal-title":"Glycobiology"},{"key":"90736_CR24","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend.11.12.0017","volume":"11","author":"H Sadeghi","year":"1997","unstructured":"Sadeghi, H., Robertson, G. L., Bichet, D. G., Innamorati, G. & Birnbaumer, M. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol. Endocrinol. 11, 1806\u20131813 (1997).","journal-title":"Mol. Endocrinol."},{"key":"90736_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.gene.2015.03.002","volume":"563","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. Compound heterozygous protein C deficiency in a family with venous thrombosis: identification and in vitro study of p.Asp297His and p.Val420Leu mutations. Gene 563, 35\u201340 (2015).","journal-title":"Gene"},{"key":"90736_CR26","doi-asserted-by":"publisher","first-page":"172803","DOI":"10.1016\/j.ejphar.2019.172803","volume":"865","author":"TB Erdem","year":"2019","unstructured":"Erdem, T. B., Mergen, H. & Saglar, O. E. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins. Eur. J. Pharmacol. 865, 172803 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"90736_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0955-0674(00)00233-7","volume":"13","author":"L Ellgaard","year":"2001","unstructured":"Ellgaard, L. & Helenius, A. ER quality control: towards an understanding at the molecular level. Curr. Opin. Cell Biol. 13, 431\u2013437 (2001).","journal-title":"Curr. Opin. Cell Biol."},{"key":"90736_CR28","doi-asserted-by":"publisher","first-page":"35678","DOI":"10.1074\/jbc.M301888200","volume":"278","author":"CM Tan","year":"2003","unstructured":"Tan, C. M., Nickols, H. H. & Limbird, L. E. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation. J. Biol. Chem. 278, 35678\u201335686 (2003).","journal-title":"J. Biol. Chem."},{"key":"90736_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1877-1173(09)89002-9","volume":"89","author":"DG Bichet","year":"2009","unstructured":"Bichet, D. G. V2R mutations and nephrogenic diabetes insipidus. Prog. Mol. Biol. Transl. Sci. 89, 15\u201329 (2009).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"90736_CR30","doi-asserted-by":"publisher","first-page":"C750","DOI":"10.1152\/ajpcell.00477.2002","volume":"285","author":"R Bouley","year":"2003","unstructured":"Bouley, R. et al. Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cells. Am. J. Physiol. Cell Physiol. 285, C750\u2013C762 (2003).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"90736_CR31","doi-asserted-by":"publisher","first-page":"16383","DOI":"10.1038\/s41598-020-73089-x","volume":"10","author":"F Prosperi","year":"2020","unstructured":"Prosperi, F. et al. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R\u2013V2R mutation. Sci. Rep. 10, 16383 (2020).","journal-title":"Sci. Rep."},{"key":"90736_CR32","doi-asserted-by":"publisher","first-page":"13416","DOI":"10.1038\/ncomms13416","volume":"7","author":"P Kumari","year":"2016","unstructured":"Kumari, P. et al. Functional competence of a partially engaged GPCR-beta-arrestin complex. Nat. Commun. 7, 13416 (2016).","journal-title":"Nat. Commun."},{"key":"90736_CR33","doi-asserted-by":"publisher","first-page":"E1028","DOI":"10.1073\/pnas.1112422109","volume":"109","author":"G Oligny-Longpre","year":"2012","unstructured":"Oligny-Longpre, G. et al. Engagement of beta-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1\/2 activation. Proc. Natl. Acad. Sci. USA. 109, E1028\u2013E1037 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"90736_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1515\/jpem-2013-0231","volume":"27","author":"CR Hong","year":"2014","unstructured":"Hong, C. R. et al. X-linked recessive nephrogenic diabetes insipidus: a clinico-genetic study. J. Pediatr. Endocrinol. Metab. 27, 93\u201399 (2014).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"90736_CR35","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1016\/j.febslet.2005.08.003","volume":"579","author":"CL Gouill","year":"2005","unstructured":"Gouill, C. L., Darden, T., Madziva, M. T. & Birnbaumer, M. A role for K268 in V2R folding. FEBS Lett. 579, 4985\u20134990 (2005).","journal-title":"FEBS Lett."},{"key":"90736_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1681\/ASN.2005080854","volume":"17","author":"V Bernier","year":"2006","unstructured":"Bernier, V. et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 17, 232\u2013243 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"90736_CR37","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-10-1927","volume":"17","author":"S Pacey","year":"2011","unstructured":"Pacey, S. et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17, 1561\u20131570 (2011).","journal-title":"Clin. Cancer Res."},{"key":"90736_CR38","doi-asserted-by":"publisher","first-page":"28831","DOI":"10.1074\/jbc.M113.464776","volume":"288","author":"C Bergmayr","year":"2013","unstructured":"Bergmayr, C. et al. Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor. J. Biol. Chem. 288, 28831\u201328844 (2013).","journal-title":"J. Biol. Chem."},{"key":"90736_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bbamcr.2010.11.020","volume":"1813","author":"CM Filipeanu","year":"2011","unstructured":"Filipeanu, C. M., de Vries, R., Danser, A. H. & Kapusta, D. R. Modulation of alpha(2C) adrenergic receptor temperature-sensitive trafficking by HSP90. Biochim. Biophys. Acta 1813, 346\u2013357 (2011).","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90736-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:41:02Z","timestamp":1670056862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90736-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90736"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90736-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11057"}}